Rainer Lueoend
Novartis (Switzerland)(CH)
Publications by Year
Research Areas
Alzheimer's disease research and treatments, Computational Drug Discovery Methods, Drug Transport and Resistance Mechanisms, Cholinesterase and Neurodegenerative Diseases, Organometallic Complex Synthesis and Catalysis
Most-Cited Works
- → A novel BACE inhibitor NB-360 shows a superior pharmacological profile and robust reduction of amyloid-β and neuroinflammation in APP transgenic mice(2015)109 cited
- → Discovery of Cyclic Sulfone Hydroxyethylamines as Potent and Selective β-Site APP-Cleaving Enzyme 1 (BACE1) Inhibitors: Structure-Based Design and in Vivo Reduction of Amyloid β-Peptides(2012)98 cited
- → Assessment of the active-site requirements of 5-aminolevulinic acid dehydratase: evaluation of substrate and product analogs as competitive inhibitors(1992)32 cited
- → Discovery of Umibecestat (CNP520): A Potent, Selective, and Efficacious β-Secretase (BACE1) Inhibitor for the Prevention of Alzheimer’s Disease(2021)32 cited
- → Discovery of cyclic sulfoxide hydroxyethylamines as potent and selective β-site APP-cleaving enzyme 1 (BACE1) inhibitors: Structure based design and in vivo reduction of amyloid β-peptides(2013)24 cited
- → .alpha.-Nitro keto hydrazone and keto imine dianions. Synthetic equivalents for the nitroalkene d3 synthon(1988)20 cited
- → Synthesis of the Potent, Selective, and Efficacious β-Secretase (BACE1) Inhibitor NB-360(2021)13 cited
- → Discovery of amino-1,4-oxazines as potent BACE-1 inhibitors(2018)11 cited
- → Discovery of Amino Alcohols as Highly Potent, Selective, and Orally Efficacious Inhibitors of Leukotriene A4 Hydrolase(2023)6 cited
- → P4‐363: THE BACE INHIBITOR NB‐360 HAS EXCELLENT BRAIN PENETRATION AND EFFICACY ON AMYLOID‐B LOAD IN ANIMAL MODELS(2014)1 cited